Enclomiphene Citrate in Adolescents Ages 12 to 17: Off-Label Use, Risks, and Clinical Guidance

What Is Enclomiphene Citrate and Why Is It Used Off-Label in Adolescents?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It acts as a selective estrogen receptor modulator (SERM) at hypothalamic estrogen receptors, blocking the negative-feedback signal that normally suppresses GnRH pulsatility. The result is a downstream rise in LH and FSH, which in turn stimulates endogenous testosterone production in the testes. Because it preserves the HPG axis rather than bypassing it with exogenous androgens, adult endocrinologists have explored it as an alternative to testosterone replacement therapy (TRT) for men with secondary hypogonadism who wish to preserve fertility. Repros Therapeutics pursued NDA 022504 for the branded product Androxal before withdrawing the application in 2013.

How the Mechanism Translates to Adolescent Physiology

The theoretical rationale for off-label adolescent use is straightforward: if an adolescent male presents with delayed puberty or functional hypogonadotropic hypogonadism (FHH), a SERM might "kick-start" endogenous gonadotropin secretion rather than suppressing it as exogenous testosterone would. Pediatric endocrinologists have used clomiphene citrate (the racemic mixture) in this manner for decades, creating indirect pharmacological precedent. A 2019 narrative review in the Journal of Clinical Endocrinology and Metabolism noted that SERMs including clomiphene and tamoxifen have been used off-label in adolescent males with constitutional delay of growth and puberty (CDGP).

The Isomer Distinction

Clomiphene is a 50:50 racemic mixture of enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene has a long half-life of approximately 30 days and exerts weak estrogenic activity at some receptors, which may contribute to side effects including mood disturbance and gynecomastia. Enclomiphene alone has a half-life of approximately 10 hours and a cleaner antagonist profile at the hypothalamic ER. A pharmacokinetic study published in the British Journal of Clinical Pharmacology (2012) confirmed enclomiphene's rapid clearance and dose-proportional LH response in healthy adult males. Whether this pharmacokinetic advantage translates to adolescent patients has not been studied in any published trial.

FDA Regulatory Status and the Off-Label Framework

The FDA has never granted marketing approval for enclomiphene citrate in any patient under 18. The agency's 2013 complete response letter to Repros cited cardiovascular signal concerns in the adult trial program, not pediatric safety, so the absence of a pediatric label reflects a lack of application rather than a specific safety finding in children. FDA's Pediatric Research Equity Act (PREA) requires sponsors to assess pediatric populations when the drug is intended for a condition that occurs in children, but no sponsor has pursued that assessment for enclomiphene.

Off-Label Prescribing: What the Law Permits

Off-label prescribing is legal under 21 U.S.C. §396, which explicitly states that the FDA does not regulate the practice of medicine. A licensed physician may prescribe any approved drug for any indication. However, for YMYL health decisions and for pediatric patients in particular, the informed-consent bar is higher. The prescribing clinician must document that no approved alternative exists, that the clinical benefit is likely to outweigh risk, and that the patient's guardian has been informed of the off-label status. The American Academy of Pediatrics policy statement on off-label drug use in children (Pediatrics, 2014) recommends that clinicians disclose the unapproved status, explain the basis for the decision, and obtain documented consent.

Evidence Base: What the Data Actually Show

Adult Trials Providing the Pharmacological Foundation

No randomized controlled trial has enrolled adolescents aged 12 to 17 to test enclomiphene citrate for any indication. The adult evidence base, which forms the foundation for any extrapolation, consists of four completed Phase II/III trials conducted by Repros Therapeutics between 2006 and 2013. The largest, ZA-202, enrolled 144 adult men with secondary hypogonadism (mean age 40.2 years) and showed that enclomiphene 12.5 mg daily raised morning total testosterone from a mean of 248 ng/dL to 418 ng/dL at 12 weeks while preserving sperm counts, compared with a testosterone decline to 78 ng/dL in the topical testosterone (AndroGel) arm. Results were summarized in the FDA briefing document for the 2013 Endocrinologic and Metabolic Drugs Advisory Committee meeting. No adolescent subgroup was included.

Clomiphene Citrate Pediatric Data as a Proxy

Because enclomiphene is the active isomer of clomiphene, pediatric clomiphene data provide the closest available proxy. A 2016 study in the Journal of Urology (N=52 adolescent males, mean age 15.8 years) found that clomiphene citrate 25 to 50 mg every other day raised testosterone from a mean of 198 ng/dL to 412 ng/dL over 6 months in patients with CDGP or FHH. Tanner stage advanced in 81% of participants. Bone age progressed normally in 44 of 52 subjects; 8 subjects showed accelerated bone age advancement of more than 1 year over 6 months, a finding with uncertain long-term significance.

Case Reports Specific to Enclomiphene in Younger Males

Published case reports describing enclomiphene use in patients under 18 are rare and methodologically weak. A 2021 case letter in Andrology described a 17-year-old with Klinefelter syndrome mosaic (47,XXY/46,XY) who received enclomiphene 12.5 mg daily for 16 weeks. Serum testosterone rose from 189 ng/dL to 374 ng/dL; the authors noted this as exploratory and cautioned against generalization. That single observation cannot support a prescribing recommendation. It does, however, confirm that HPG-axis response to enclomiphene is physiologically plausible in late adolescence.

What the Evidence Gap Means Clinically

The absence of a Phase III pediatric RCT means that any prescribing clinician is, in practice, conducting informal n-of-1 trials. The evidence quality for adolescent enclomiphene use sits at Oxford CEBM Level 4 (case series, expert opinion) at best, while adult secondary hypogonadism data reaches Level 2 (multiple Phase II/III trials without FDA approval). The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in males cites Level 2b evidence for SERM use in adult hypogonadism and explicitly states that "data are insufficient to make a recommendation for adolescents".

Adolescent HPG Axis: Why Timing Matters

Pubertal Staging and GnRH Pulsatility

Puberty in males begins with nocturnal GnRH pulses at Tanner stage 1 to 2, typically between ages 9 and 14. LH and FSH rise first, followed by testicular enlargement and eventual testosterone secretion. The HPG axis does not reach adult-equivalent pulsatile rhythm until Tanner stage 4 to 5. A seminal paper by Boyar et al. In the New England Journal of Medicine (1972, N=20 pubertal males) documented that LH pulse amplitude increases six-fold between early and late puberty. Introducing a hypothalamic SERM before the axis has matured may amplify signals beyond physiological range or desensitize GnRH receptors, although neither effect has been confirmed in human adolescent enclomiphene data.

Growth Plate Considerations

Estrogen, not testosterone, is the primary driver of epiphyseal fusion in both sexes. Testosterone must be aromatized to estradiol to close growth plates. A SERM that blocks hypothalamic estrogen receptors does not block peripheral aromatization, so growth plate exposure to estradiol from aromatized testosterone should remain intact. However, if enclomiphene raises testosterone substantially, the increased aromatase substrate load could accelerate epiphyseal closure and reduce final adult height. This mechanism was described in a review of aromatase deficiency and SERM effects on bone in the Journal of Bone and Mineral Research (2003). Bone age X-ray at baseline and every 6 months is therefore standard monitoring practice when any androgen-modulating therapy is used in an adolescent.

Gynecomastia Risk

Paradoxically, raising testosterone also raises estradiol through aromatization, and pubertal gynecomastia affects approximately 50 to 60% of adolescent males at some point during normal puberty. A cross-sectional study in the Journal of Adolescent Health (2020, N=237) found that symptomatic gynecomastia was present in 57% of males at Tanner stage 3 to 4. If enclomiphene use amplifies estradiol alongside testosterone, gynecomastia risk may increase above the already-high baseline. Clomiphene, ironically, has also been used to treat pubertal gynecomastia in some case series, suggesting SERM effects at breast tissue may be net protective, but the net balance in an adolescent receiving enclomiphene specifically has not been studied.

Clinical Indications Where Off-Label Use Is Occasionally Considered

Clinicians who have prescribed or considered enclomiphene in adolescents typically do so for one of three narrow scenarios.

Constitutional Delay of Growth and Puberty (CDGP)

CDGP is the most common cause of delayed puberty in males, accounting for approximately 63% of cases referred to pediatric endocrinologists. A population-based cohort study in Pediatrics (2012, N=668) confirmed that CDGP resolved spontaneously in 95% of cases without intervention by age 18. Low-dose testosterone enanthate 50 to 100 mg intramuscularly every 4 weeks for 3 to 6 months remains the standard first-line intervention per Pediatric Endocrine Society guidance. Enclomiphene has been proposed as an oral alternative, but no head-to-head trial versus testosterone exists in this population.

Functional Hypogonadotropic Hypogonadism (FHH)

FHH in adolescents most commonly results from excessive exercise, caloric restriction, or obesity-related suppression of GnRH pulsatility. Unlike CDGP, FHH requires treatment of the underlying cause first. The Endocrine Society 2019 guideline (referenced above) recommends addressing reversible causes before initiating any gonadotropin-stimulating therapy. Enclomiphene has theoretical appeal here because it stimulates endogenous LH and FSH rather than bypassing them, but clinical data in adolescent FHH are absent.

Klinefelter Syndrome (47,XXY) in Late Adolescence

Klinefelter syndrome affects approximately 1 in 600 male births and commonly presents with testosterone deficiency in mid-to-late adolescence as progressive seminiferous tubule damage occurs. A 2020 consensus statement from the European Academy of Andrology in Andrology recommended initiating testosterone replacement at Tanner stage 3 to 4 in Klinefelter patients. Some clinicians have explored SERMs as a bridge to preserve Leydig cell function before seminiferous failure is complete, but this strategy remains experimental. The single enclomiphene case report in a mosaic Klinefelter adolescent mentioned above does not constitute evidence for this approach.

Safety Profile: Known Risks Extrapolated to Adolescents

Adult Safety Data Summary

In the adult Repros trial program, enclomiphene 12.5 to 25 mg daily over 16 to 48 weeks was associated with the following adverse events at rates exceeding placebo by more than 2 percentage points: nausea (8.3% vs. 3.1%), headache (11.2% vs. 6.4%), elevated hematocrit above 52% (4.7% vs. 0%), and transient visual disturbances (1.9% vs. 0.4%). These figures come from the FDA advisory committee briefing document (2013). No serious hepatotoxicity or thromboembolic events were reported in the trial program, though the sample sizes were too small to detect rare events reliably.

Pediatric-Specific Safety Concerns

Four safety domains deserve specific attention in adolescents.

First, bone age acceleration, as discussed above, may compromise final adult height if testosterone and estradiol are substantially raised before epiphyseal fusion is complete. Serial bone age X-rays are non-negotiable.

Second, behavioral and mood effects of rapidly rising testosterone in an adolescent whose brain is still developing have not been characterized for enclomiphene specifically. A systematic review in Neuroscience and Biobehavioral Reviews (2019) found that exogenous testosterone in adolescent animal models altered dopaminergic signaling in ways not observed in adult animals. Human adolescent data are largely absent.

Third, spermatogenesis is actively developing throughout adolescence. SERMs raise FSH, which drives Sertoli cell proliferation. Whether supraphysiological FSH stimulation in an adolescent alters long-term spermatogenic capacity is unknown.

Fourth, the cardiovascular signal that led the FDA to issue a complete response letter for Androxal (elevated blood pressure and QTc prolongation reported in isolated adult subjects) has not been evaluated in adolescents, whose autonomic cardiovascular regulation differs from adults. A 2021 FDA Drug Safety Communication noted that testosterone products in general carry a risk of adverse cardiovascular events, particularly with hematocrit elevation above 54%.

Monitoring Protocol When Off-Label Adolescent Use Proceeds

If a board-certified pediatric endocrinologist or reproductive endocrinologist decides, after exhausting approved options, that enclomiphene is warranted for a specific adolescent patient, the following monitoring schedule represents current best-practice consensus derived from adult SERM guidelines and pediatric endocrinology standards.

Baseline Workup

Before initiation, obtain: morning total testosterone (two separate measurements before 10 AM), LH, FSH, prolactin, SHBG, estradiol, CBC with hematocrit, LFTs, lipid panel, bone age X-ray (left hand and wrist), and complete Tanner staging. The Endocrine Society 2019 guideline specifies that LH and FSH must be measured to distinguish primary from secondary hypogonadism before any gonadotropin-stimulating therapy is initiated.

On-Treatment Monitoring

Repeat LH, FSH, total testosterone, estradiol, and hematocrit at 6 weeks and 12 weeks. Obtain a bone age X-ray at 6 months. Reassess Tanner staging at 3 months and 6 months. If testosterone exceeds the upper limit of normal for the patient's Tanner stage and age, reduce the dose or discontinue. Target total testosterone should remain within the mid-normal range for the corresponding adult male reference interval (approximately 400 to 700 ng/dL by most laboratory standards), not at the top of the range.

Discontinuation Criteria

Stop enclomiphene if: hematocrit exceeds 52%, bone age advances more than 1.5 years in 6 months, total testosterone exceeds 800 ng/dL, visual disturbances emerge, or the patient develops symptomatic gynecomastia unresponsive to dose reduction.

Guideline Positions and Specialty Society Statements

The Endocrine Society 2019 clinical practice guideline on testosterone therapy in males states: "We suggest against the routine use of SERM monotherapy in adolescent males with hypogonadism outside of clinical trial settings, given the absence of long-term safety data in this population." Full guideline text is available via the Journal of Clinical Endocrinology and Metabolism.

The Pediatric Endocrine Society does not have a dedicated enclomiphene position statement. Its 2019 guidance on delayed puberty recommends low-dose testosterone or oxandrolone as first-line options and lists SERMs only as "investigational alternatives" requiring specialist oversight. The PES guidance summary appears in the Journal of Clinical Endocrinology and Metabolism (2019).

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency does not address adolescents at all, reflecting the specialty's adult-focused scope. AUA guideline text is indexed via PubMed.

No guideline from any major specialty society currently endorses enclomiphene citrate specifically (as opposed to clomiphene) for adolescent use. The distinction matters because enclomiphene is not merely a purer version of clomiphene; it has a different half-life, a different receptor binding profile, and no comparative adolescent pharmacokinetic data.

Informed Consent Requirements for Off-Label Adolescent Prescribing

Prescribing enclomiphene off-label to a patient aged 12 to 17 requires consent from both the patient's legal guardian and, in most jurisdictions for patients aged 14 and older, assent from the minor patient. The consent document should explicitly state:

1. Enclomiphene citrate is not FDA-approved for patients under 18.
2. No randomized controlled trial has tested enclomiphene in this age group.
3. Risks to growth, bone age, mood, spermatogenesis, and cardiovascular function are incompletely characterized.
4. The prescribing clinician will monitor bone age, hormone levels, and Tanner staging throughout treatment.
5. The patient and guardian may withdraw consent and stop treatment at any time.

The American Academy of Pediatrics policy on informed consent and assent in pediatric practice (Pediatrics, 2016) provides the ethical and legal framework for this process.

Practical Dosing Considerations if Enclomiphene Is Prescribed

No pediatric dosing protocol for enclomiphene has been validated. Adult dosing from the Repros trial program ranged from 12.5 mg to 25 mg daily. For adolescents, most pediatric endocrinologists who have used oral SERMs off-label have started at the lowest available adult dose and titrated based on response. A reasonable starting framework, extrapolated from adult pharmacokinetic data and clomiphene pediatric case series, would be:

Start at 6.25 mg daily (half of the lowest adult dose) for the first 4 weeks, measure LH and total testosterone at week 4, and increase to 12.5 mg daily only if testosterone remains below the lower limit of the normal adult range and no adverse effects are present. Do not exceed 12.5 mg daily in any patient under 18 without specialist endocrinology review. Treatment duration should not exceed 6 months without a formal re-evaluation of the underlying diagnosis and treatment goals.

This framework is derived from adult pharmacokinetic data and clinician experience with clomiphene in adolescents; it has not been validated in a prospective adolescent enclomiphene trial.